Markets

Why BioNTech and Moderna Stocks Are Slipping Today

What happened

Shares of BioNTech (NASDAQ: BNTX) were down 5.3% as of 10 a.m. EDT on Tuesday. Meanwhile, shares of Moderna (NASDAQ: MRNA) were slipping 2.7%.

There appear to be two common denominators between the declines of these two vaccine stocks. First, the overall stock market fell this morning. Second, the Israeli Health Ministry announced that the COVID-19 vaccine developed by Pfizer (NYSE: PFE) and BioNTech appears to be less effective against the Delta variant, a coronavirus strain that's spreading rapidly.

Healthcare professional giving a shot to a person.

Image source: Getty Images.

So what

Many stocks fall when the overall market drops. However, the news from Israel appears to be causing the shares of BioNTech and Moderna to take a harder hit than many other stocks.

The Israeli Health Ministry stated that the Pfizer-BioNTech vaccine is 64% effective in preventing infection and symptomatic disease. That's a sharp decline from the vaccine's initially reported efficacy. The change appears to be related to the increase in the spread of the Delta variant.

Investors viewed this as especially bad news for BioNTech. All of the German biotech's revenue currently stems from sales of the COVID vaccine that it co-markets with Pfizer.

The data from Israel didn't address Moderna's COVID vaccine. However, the report was seen as potentially negative for Moderna because its vaccine, like the Pfizer-BioNTech vaccine, is based in messenger RNA (mRNA) technology.

There was some good news with the Israeli Health Ministry announcement, though. The Pfizer-BioNTech vaccine was 93% effective in preventing hospitalizations and serious illness, close to its previously reported efficacy levels.

Now what

The Pfizer-BioNTech and Moderna teams are conducting clinical studies of booster doses that target coronavirus variants. With the lower efficacy reported from Israel, the results from these studies could be even more important to the companies' fortunes.

10 stocks we like better than BioNTech SE
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and BioNTech SE wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of June 7, 2021

Keith Speights owns shares of Pfizer. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BNTX PFE MRNA

Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More